Nikkei 225 Stock Average Rebalancing – January 2025
As per the “Periodic Review” conducted twice a year by Nikkei Inc. (Nikkei), the constituents of Nikkei 225 will be reviewed and changed at the end...
291 Views
Shimadzu (7701) To Buy Out Nissui Pharma (4550) In Tender Offer
Nissui (1332) is finally letting go of its perpetually cash-rich subsidiary Nissui Pharma (4550) in a weird multi-step tender which is tough to...
673 Views
Opdivo Singled Out in Government Rule Change
The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...
5.7k Views
No more insights